latest news releases from the newsroom
Neoware to Present at Needham & Company Growth Conference
KING OF PRUSSIA, Pa., Jan. 4, 2006 (PRIMEZONE) -- Neoware, Inc. (Nasdaq:NWRE), the leading supplier of enterprise thin client solutions, and related software and services that make computing more open, secure, reliable, affordable, and manageable, today announced that the Company will present at the Needham & Company, LLC Growth Conference.
J.P. Morgan Chase & Co.'s Holdings in Metso to 4.76 Percent
HELSINKI, Finland, Jan. 4, 2006 (PRIMEZONE) -- Metso Corporation has been informed about a decrease in the holding of the mutual funds managed by J.P. Morgan Chase & Co. of the paid up share capital of Metso Corporation. On December 29, 2005, J.P. Morgan Chase & Co. 's holdings amounted to 4.76 percent of the paid up share capital of Metso Corporation after being, on the basis of their previous announcement, 5.33 percent on November 9, 2005. The threshold of five percent was crossed on December 29, 2005 when J.P. Morgan Securities Ltd. sold 460,000 Metso shares.
TDC A/S: Holding of Own Shares
COPENHAGEN, Denmark, Jan. 4, 2006 (PRIMEZONE) -- Pursuant to Section 204.33 of the New York Stock Exchange Listed Company Manual, this is to report that TDC A/S on December 31, 2005 held 3,661,655 of its own shares of DKK 5, corresponding to a total nominal value of DKK 18,308,275 or 1.85% of the total share capital.
Marine Harvest Obtains EUR 300 Million Revolving Credit Facility
LONDON, Jan. 4, 2006 (PRIMEZONE) -- Stolt-Nielsen S.A. (Nasdaq:SNSA) (Oslo Stock Exchange:SNI) announces that Marine Harvest N.V., the joint venture of Nutreco Holding N.V. and Stolt-Nielsen S.A., has obtained underwriting commitments from a group of four international banks for a five-year EUR 300 million unsecured revolving credit facility. Closing of this facility is subject to documentation and is expected to occur in the first quarter of 2006.
Epigenomics AG adds Regulatory Affairs and Marketing Expertise to Senior Management
BERLIN and SEATTLE, Jan. 4, 2006 (PRIMEZONE) -- Epigenomics AG (Frankfurt:ECX) (Prime Standard:ECX), a molecular diagnostics company developing tests based on DNA methylation, announced today the addition of Dr. Michael Wandell as Senior Vice President for Clinical, Regulatory and Quality, and James Douglas as Vice President Marketing and Sales to its senior management team. These appointments position the company to fully realize its own tissue-based molecular pathology product development. For the foreseeable future, the company considers the building of a senior management team for an integrated product company complete. Both Dr. Wandell and Mr. Douglas will be based in Seattle. Epigenomics also sees these additions as a clear statement to leverage its Seattle base to deliver its products to the U.S. market, though it will continue to base the main part of its research and development organization in Berlin and eventually market its products worldwide.
Epigenomics Successfully Completes Biomarker Validation Study for Prostate Cancer Classification Test
BERLIN and SEATTLE, Jan. 4, 2006 (PRIMEZONE) -- Epigenomics AG (Frankfurt:ECX) (Prime Standard:ECX), a molecular diagnostics company developing tests based on DNA methylation, announced today the successful completion of a 605 patient study validating three of its proprietary DNA methylation markers as clinically useful indicators of prostate cancer aggressiveness. Epigenomics, which during 2005 prepared to initiate its own development of molecular pathology products, also announced the development of the test as its own product, following Roche Diagnostics' decision to discontinue the collaborative development of the prostate cancer molecular classification test and to not maintain their option rights to an exclusive license.